338 related articles for article (PubMed ID: 18439942)
1. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas.
Gejman R; Swearingen B; Hedley-Whyte ET
Hum Pathol; 2008 May; 39(5):758-66. PubMed ID: 18439942
[TBL] [Abstract][Full Text] [Related]
2. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
[TBL] [Abstract][Full Text] [Related]
3. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
[TBL] [Abstract][Full Text] [Related]
4. A classification tree approach for pituitary adenomas.
Righi A; Agati P; Sisto A; Frank G; Faustini-Fustini M; Agati R; Mazzatenta D; Farnedi A; Menetti F; Marucci G; Foschini MP
Hum Pathol; 2012 Oct; 43(10):1627-37. PubMed ID: 22446019
[TBL] [Abstract][Full Text] [Related]
5. [Significance of p53 protein expression and proliferative potential with MIB-1 on tumor recurrence of pituitary adenomas].
Miyagami M; Nakamura S
No To Shinkei; 1998 Jan; 50(1):27-32. PubMed ID: 9493195
[TBL] [Abstract][Full Text] [Related]
6. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E
Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
[TBL] [Abstract][Full Text] [Related]
7. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results.
Losa M; Franzin A; Mangili F; Terreni MR; Barzaghi R; Veglia F; Mortini P; Giovanelli M
Neurosurgery; 2000 Dec; 47(6):1313-8; discussion 1318-9. PubMed ID: 11126902
[TBL] [Abstract][Full Text] [Related]
8. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
Matsuyama J
Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
[TBL] [Abstract][Full Text] [Related]
10. CD147 expression in pituitary adenomas and its significance for clinical outcome.
Qu X; Yang W; Jiang M; Han T; Han L; Qu Y; Wang G; Shi D; Xu G
Hum Pathol; 2010 Aug; 41(8):1165-71. PubMed ID: 20381119
[TBL] [Abstract][Full Text] [Related]
11. The abnormalities in the p53/p21WAF1 pathway have a significant role in the pathogenesis and progression of gastrointestinal stromal tumors.
Chou YP; Lin JW; Wang CC; Chiu YC; Huang CC; Chuah SK; Tai MH; Yi LN; Lee CM; Changchien CS; Hu TH
Oncol Rep; 2008 Jan; 19(1):49-56. PubMed ID: 18097575
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of proliferation biomarkers and p53 expression in rectal mucosa and sporadic colonic adenomas: a prospective study.
Freitas D; Goulão MH; Camacho E; Figueiredo P; Ministro P; Ferreira M; Portela F; Andrade P; Donato A; Martins MI
Hepatogastroenterology; 2002; 49(47):1269-74. PubMed ID: 12239922
[TBL] [Abstract][Full Text] [Related]
13. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
[TBL] [Abstract][Full Text] [Related]
14. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.
Wolfsberger S; Wunderer J; Zachenhofer I; Czech T; Böcher-Schwarz HG; Hainfellner J; Knosp E
Acta Neurochir (Wien); 2004 Aug; 146(8):831-9. PubMed ID: 15254805
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of p53 and Ki-67 expression in resected or biopsy specimens of bile duct carcinoma.
Murakami M; Sasaki T; Kuwada Y; Yamasaki S; Kuwahara K; Chayama K
Oncol Rep; 2003; 10(5):1091-6. PubMed ID: 12883663
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas.
Liu W; Kunishio K; Matsumoto Y; Okada M; Nagao S
J Clin Neurosci; 2005 Sep; 12(7):791-4. PubMed ID: 16198918
[TBL] [Abstract][Full Text] [Related]
18. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
[TBL] [Abstract][Full Text] [Related]
19. Pathobiology of pituitary adenomas and carcinomas.
Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
[TBL] [Abstract][Full Text] [Related]
20. Biologic markers of invasive pituitary adenomas involving the sphenoid sinus.
Gandour-Edwards R; Kapadia SB; Janecka IP; Martinez AJ; Barnes L
Mod Pathol; 1995 Feb; 8(2):160-4. PubMed ID: 7777477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]